Variation of immunological response in methotrexate-induced pneumonitis

Rheumatology

Volumn 47, Issue 11, 2008, Pages 1647-1650

  Chikura, B ^a   Sathi, N ^b   Lane, S ^b   Dawson, J K ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bronchoalveolar lavage; Delayed hypersensitivity; Immunology; Interstitial lung disease; Lung biopsy; Lung fibrosis; Methotrexate; Pneumonitis

Indexed keywords

ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LOW DRUG DOSE; LUNG BIOPSY; LUNG FIBROSIS; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; PATHOPHYSIOLOGY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BRONCHOALVEOLAR LAVAGE FLUID; DATABASES, BIBLIOGRAPHIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG; LYMPHOCYTES; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPHILS; PNEUMONIA; STATISTICS, NONPARAMETRIC;

EID: 54449098254     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken356     Document Type: Article

References (56)

1. Chan V, Tett SE. Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004. Pharmacoepidemiol Drug Saf 2006;15:462-8.
2. Gibofsky A, Palmer WR, Goldman JA et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: The RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention And Utilization Study) study. Curr Med Res Opin 2006;22:169-83.
3. Bolla G, Disdier P, Harle JR, Verrot D, Weiller PJ. Concurrent acute megaloblastic anaemia and pneumonitis: A severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis. Clin Rheumatol 1993;12:535-7.
4. Cannon GW, Ward JR, Clegg DO, Samuelson CO Jr, Abbott TM. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983;26:1269-74.
5. Clearkin R, Corris PA, Thomas SH. Methotrexate pneumonitis in a patient with rheumatoid arthritis. Postgrad Med J 1997;73:603-4.
6. Cook NJ, Carroll GJ. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:272-4.
7. De BM, Rat AC, Palazzo E, Kahn MF. Delayed methotrexate pneumonitis. J Rheumatol 1991;18:1943.
8. Elsasser S, Dalquen P, Soler M, Perruchoud AP. Methotrexate-induced pneumonitis: Appearance four weeks after discontinuation of treatment. Am Rev Respir Dis 1989;140:1089-92.
9. Engelbrecht JA, Calhoon SL, Scherrer JJ. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 1983;26:1275-8.
10. From E. Methotrexate pneumonitis in a psoriatic. Br J Dermatol 1975;93:107-10.
11. Goldman GC, Moschella SL. Severe pneumonitis occurring during methotrexate therapy. Report of two cases. Arch Dermatol 1971;103:194-7.
12. Green L, Schattner A, Berkenstadt H. Severe reversible interstitial pneumonitis induced by low dose methotrexate: Report of a case and review of the literature. J Rheumatol 1988;15:110-2.
13. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: Report of five cases and review of published reports. Thorax 1992;47:628-33.
14. Hassan W, Carpenter M, Kelly C. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis. Thorax 1993;48:191.
15. Kerstens PJ, Van Loenhout JW, Boerbooms AM, Van De Putte LB. Methotrexate, pneumonitis, and infection. Ann Rheum Dis 1992;51:1179-80.
16. Leduc D, De VP, Lheureux P, Gevenois PA, Jacobovitz D, Yernault JC. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993;104:1620-3.
17. Mulherin D, Cummiskey JM, Doyle GD, FitzGerald O. Methotrexate pneumonitis in rheumatoid arthritis - a dramatic response to treatment. Br J Rheumatol 1992;31:356-7.
18. Newman ED, Harrington TM. Fatal methotrexate pneumonitis in rheumatoid arthritis. Arthritis Rheum 1988;31:1585-6.
19. Ohosone Y, Okano Y, Kameda H et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997;24:2299-303.
20. Pourel J, Guillemin F, Fener P, Webanck L, Bene MC, Delorme N. Delayed methotrexate pneumonitis in rheumatoid arthritis. J Rheumatol 1991;18:303-4.
21. Ridley MG, Wolfe CS, Mathews JA. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: A case report and review of the literature. Ann Rheum Dis 1988;47:784-8.
22. Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: Report of five cases and review of the literature. Clin Rheumatol 1997;16:296-304.
23. Schoenfeld A, Mashiach R, Vardy M, Ovadia J. Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy. Obstet Gynecol 1992;80:520-1.
24. Schwartz GF, Anderson ST. Methotrexate induced pneumonitis in a young woman with psoriasis and rheumatoid arthritis. J Rheumatol 1990;17:980.
25. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164-71.
26. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994;107:266-70.
27. St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985;145:2035-8.
28. Stenger AA, Houtman PM. Methotrexate, pneumonitis, and infection. Ann Rheum Dis 1992;51:1179-80.
29. Tsai JJ, Shin JF, Chen CH, Wang SR. Methotrexate pneumonitis in bronchial asthma. Int Arch Allergy Immunol 1993;100:287-90.
30. van der Veen MJ, Dekker JJ, Dinant HJ, van Soesbergen RM, Bijlsma JW. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995;22:1766-8.
31. Bartram SA. Experience with methotrexate-associated pneumonitis in northeastern England: Comment on the article by Kremer et al. Arthritis Rheum 1998;41:1327-8.
32. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
33. Weiner RS, Bortin MM, Gale RP et al. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med 1986; 104:168-75.
34. Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996;35:441-5.
35. Inui N, Chida K, Suda T, Nakamura H. TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis. J Allergy Clin Immunol 2001;107:337-44.
36. Prasse A, Georges CG, Biller H et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol 2000;122:241-8.
37. Hunninghake GW, Fulmer JD, Young RC Jr, Gadek JE, Crystal RG. Localization of the immune response in sarcoidosis. Am Rev Respir Dis 1979;120:49-57.
38. Mornex JF, Cordier G, Pages J et al. Activated lung lymphocytes in hypersensitivity pneumonitis. J Allergy Clin Immunol 1984;74:719-27.
39. Akoun GM, Gauthier-Rahman S, Mayaud CM, Touboul JL, Denis MF. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 1987;91:96-9.
40. Vega A, Cabanas R, Contreras J et al. Anaphylaxis to methotrexate: a possible IgE-mediated mechanism. J Allergy Clin Immunol 1994;94:268-70.
41. Schnabel A, Richter C, Bauerfeind S, Gross WL. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997;52:377.
42. Richerson HB, Coon JD, Lubaroff D. Selective early increases of bronchoalveolar CD8+ lymphocytes in a LEW rat model of hypersensitivity pneumonitis. J Allergy Clin Immunol 1995;96:113-21.
43. Turesson C, Matteson EL, Colby TV et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005;52:73-9.
44. Enelow RI, Mohammed AZ, Stoler MH et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998;102:1653-61.
45. Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 1997;112:1338-43.
46. Crestani B, Dehoux M, Hayem G et al. Differential role of neutrophils and alveolar macrophages in hepatocyte growth factor production in pulmonary fibrosis. Lab Invest 2002;82:1015-22.
47. Rosner V, Chabot F, Moreau L, Grignon Y, Delorme N, Polu JM. Contribution of bronchoalveolar lavage and transbronchial biopsy to diagnosis and prognosis of drug-induced pneumopathies. Rev Pneumol Clin 1995;51:269-74.
48. Sato E, Camhi SL, Koyama S, Robbins RA. Methotrexate stimulates lung fibroblasts and epithelial cells to release eosinophil chemotactic activity. J Rheumatol 2001;28:502-8.
49. Pardo A, Barrios R, Gaxiola M et al. Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Am J Respir Crit Care Med 2000;161:1698-704.
50. Hwang SJ, Kim S, Park WS, Chung DH. IL-4-secreting NKT cells prevent hypersensitivity pneumonitis by suppressing IFN-gamma-producing neutrophils. J Immunol 2006;177:5258-68.
51. Lee DG, Cho BH, Hervey J, Daynes RA. The role of neutrophils in tissue localized cell-mediated immunologic responses: I. The intensity of contact-type and delayed-type hypersensitivity responses may be influenced by the extent of extracellular matrix degradation by neutrophil proteases. Reg Immunol 1988;1:149-62.
52. Morris PE, Glass J, Cross R, Cohen DA. Role of T-lymphocytes in the resolution of endotoxin-induced lung injury. Inflammation 1997;21:269-78.
53. Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985;40:501-7.
54. van Ede AE, Laan RF, Blom HJ, De Abreu RA, Van De Putte LB. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
55. Leeb BF, Smolen JS. Low dose methotrexate therapy in chronic polyarthritis - an update. Acta Med Austriaca 1996;23:114-9.
56. Kamen BA, Nylen PA, Camitta BM, Bertino JR. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 1981;41:355-60.